SELLAS Life Sciences (SLS) Non-Current Assets (2010 - 2026)

SELLAS Life Sciences (SLS) has 17 years of Non-Current Assets data on file, last reported at $3.0 million in Q1 2026.

• Non-Current Assets for Q1 2026 came in at $3.0 million, up 0.84% year-over-year; the trailing twelve-month figure through Mar 2026 was $11.5 million (up 1.13% YoY), and the FY2025 annual result was $3.1 million, up 0.93% from the prior year.
• Non-Current Assets declined to $3.0 million in Q1 2026 per SLS's latest filing, from $3.1 million in the prior quarter.
• Over five years, Non-Current Assets peaked at $3.6 million in Q1 2022 and troughed at $2.5 million in Q3 2024.
• A 5-year average of $3.0 million and a median of $3.0 million in 2026 frame the typical range for Non-Current Assets.
• The sharpest annual moves came in 2022 and 2024: Non-Current Assets tumbled 62.17% in 2022, then rose 1.9% in 2024.
• A 5-year view of Non-Current Assets shows it stood at $3.2 million in 2022, then retreated by 4.39% to $3.0 million in 2023, then increased by 1.9% to $3.1 million in 2024, then grew by 0.93% to $3.1 million in 2025, then slipped by 4.02% to $3.0 million in 2026.
• Business Quant data shows SLS's Non-Current Assets at $3.0 million in Q1 2026, $3.1 million in Q4 2025, and $2.5 million in Q3 2025.